anti human stat1 (Cell Signaling Technology Inc)
Structured Review

Anti Human Stat1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 980 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+human+stat1/Stat1+Rabbit+mAb/pmc13036235-193-18-21
Average 97 stars, based on 980 article reviews
Images
1) Product Images from "IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy"
Article Title: IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy
Journal: Frontiers in Immunology
doi: 10.3389/fimmu.2026.1772472
Figure Legend Snippet: CART-induced GUCY2C loss is mediated by the IFNγ-JAK-STAT1 signaling axis. (A) LS174T cells and orthogonal approaches of cytokine screening (B) and confirmation (C) , IFNγ neutralizing antibody (D) , pharmacologic JAK1/2 blockade with ruxolitinib (E) , and JAK1/2 genetic knockout (F) were used to define the role of the IFNγ-JAK-STAT signaling axis in GUCY2C loss. (B) LS174T cells were treated with GM-CSF (20 ng/mL), TNFα (1 ng/mL), IL-8 (2 ng/mL), MIP-1α (2 ng/mL), MIP-1β (2 ng/mL), or IFNγ (15 ng/mL) for 48 hours, and GUCY2C protein levels were quantified. (C) LS174T cells were treated with 150 ng/mL IFNγ for 48 hours, and pSTAT1 and GUCY2C protein levels were quantified. (D–F) LS174T cells were treated with conditioned media (CM) for 48 hours from control or anti-CD3/CD2/CD28 bead-activated T cells, and pSTAT1 and GUCY2C protein levels were quantified; (D) 13 μg/mL anti-IFNγ neutralizing antibody was included in some conditions; (E) 2.5 μM ruxolitinib was included in some conditions; (F) LS174T cell pools previously treated with control CRISPR/Cas9 or JAK1 + 2 CRISPR/Cas9 were used. Each data point in (B–F) represents average of biological replicates from separate experiments (N = 3–4 experiments). In (C–F) , pSTAT, GUCY2C, and housekeeping control were examined on the same blot. The housekeeping protein is shown only below GUCY2C. A paired t-test was used to compare the two conditions in (C) ; in (B) and (D–F) , one-way ANOVA was used to compare each condition to the control treatment, and additional comparisons are indicated by bars; ns = p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Figure schematics were generated using BioRender.com .
Techniques Used: Knock-Out, Control, CRISPR, Generated
Related Articles
Blocking Assay:Article Title: Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds Article Snippet: .. Antibodies used included monoclonal anti-human AURKA (1:2000, Cell Signaling Technology), Article Title: Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds. Article Snippet: .. Antibodies used included monoclonal anti-human AURKA (1:2000, Cell Signaling Technology), Incubation:Article Title: 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine Article Snippet: Membranes were blocked in 5% nonfat dry milk (Biorad blotting-grade blocker cat# 170-6404) in 1XPBST (0.05% Tween in 1XPBS buffer, Millipore Sigma cat# P9416 and Millipore Sigma cat# 11666789001, respectively), for 1 h at room temperature. .. Membranes were then incubated overnight at 4 °C with the following primary antibodies: IDO1 clone 2E2 (dilution 1:2000) (Enzo Lifescience, cat# ALX-804-902-0100); IDO2 (dilution 1:500) (Santa Cruz, cat# sc-374159); Article Title: Chitosan/poly(γ-glutamic acid) nanoparticles incorporating IFN-γ for immune response modulation in the context of colorectal cancer. Article Snippet: IFN-γ therapy has been approved by the Food and Drug Administration (FDA) for the treatment of chronic granulomatous disease and severe malignant osteopetrosis.. Despite the promising IFN-γ-based therapeutic applications, its limited success in clinical trials is related with limitations inherent to its molecular properties and with the difficulties to deliver it locally or with adequate periodicity to achieve a therapeutic effect.. We have previously shown that chitosan (Ch)/poly(γ-glutamic acid) (γ-PGA) nanoparticles (NPs) are immunostimulatory, impairing colorectal cancer cell invasion. Western Blot:Article Title: Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages Article Snippet: Antibody , Mouse monoclonal anti‐human MerTK (clone 590H11G1E3) , Biolegend , Cat# 367607 RRID: AB_2566400 , FACS (1 μg/mL). .. Antibody , Rabbit monoclonal anti‐human STAT1 (clone 42H3) , Cell Signaling Technology , Cat# 9175 RRID: AB_2197984 , WB (1:100). .. Antibody , Rabbit anti‐human actin (a.a. 20‐33) , Sigma‐Aldrich , Cat# A5060 RRID: AB_476738 , WB (1:100). other:Article Title: Involvement of signal transducers and activators of transcription in trophoblast differentiation. Article Snippet: Introduction: To explore the involvement of signal transducers and activators of transcription (STATs) in trophoblast differentiation.. Methods and results: First, the localization of STATs in human placentas was detected via immunohistochemistry (IHC) and immunofluorescence (IF).. Cytotrophoblasts (CTBs) expressed both STAT1 and 3, but syncytiotrophoblasts (STBs) did not. Article Title: Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Article Snippet: At the end of culture, live tumor cells were quantified by adding D-luciferin (150 μg/ml; Caliper Life Science) to cell cultures and reading out luciferase activities using an Infinite M1000 microplate reader (Tecan). |

